The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prognostic factors for long-term overall survival (OS) for patients (pts) undergoing first-line treatment for metastatic colorectal cancer (mCRC) with chemotherapy (CT) plus bevacizumab (bev): Findings from a large observational study.
Dirk Arnold
Consultant or Advisory Role - Roche (U)
Honoraria - Roche
Research Funding - Roche
Wilfried Grothe
No relevant relationships to disclose
Dirk Tummes
Research Funding - Roche
Manfred Kindler
No relevant relationships to disclose
Volker Petersen
No relevant relationships to disclose
Stefanie Boszeit-Luft
No relevant relationships to disclose
Joerg Seraphin
No relevant relationships to disclose
Andreas Kutscheidt
No relevant relationships to disclose